Janux Therapeutics (JANX) Operating Expenses: 2020-2025
Historic Operating Expenses for Janux Therapeutics (JANX) over the last 6 years, with Sep 2025 value amounting to $45.3 million.
- Janux Therapeutics' Operating Expenses rose 24.72% to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.3 million, marking a year-over-year increase of 55.83%. This contributed to the annual value of $109.4 million for FY2024, which is 35.00% up from last year.
- Latest data reveals that Janux Therapeutics reported Operating Expenses of $45.3 million as of Q3 2025, which was up 0.29% from $45.1 million recorded in Q2 2025.
- Janux Therapeutics' Operating Expenses' 5-year high stood at $45.3 million during Q3 2025, with a 5-year trough of $2.7 million in Q1 2021.
- In the last 3 years, Janux Therapeutics' Operating Expenses had a median value of $22.7 million in 2024 and averaged $28.7 million.
- Per our database at Business Quant, Janux Therapeutics' Operating Expenses soared by 860.35% in 2021 and then decreased by 11.90% in 2023.
- Over the past 5 years, Janux Therapeutics' Operating Expenses (Quarterly) stood at $15.1 million in 2021, then skyrocketed by 39.75% to $21.1 million in 2022, then declined by 11.90% to $18.6 million in 2023, then surged by 56.05% to $29.0 million in 2024, then rose by 24.72% to $45.3 million in 2025.
- Its Operating Expenses stands at $45.3 million for Q3 2025, versus $45.1 million for Q2 2025 and $34.9 million for Q1 2025.